- Home
- FT vs FENC Comparison
FT vs FENC Comparison
Compare FT & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- FENC
- Stock Information
- Founded
- FT 1988
- FENC 1996
- Country
- FT United States
- FENC United States
- Employees
- FT N/A
- FENC N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FT Finance
- FENC Health Care
- Exchange
- FT Nasdaq
- FENC Nasdaq
- Market Cap
- FT 190.4M
- FENC 156.9M
- IPO Year
- FT N/A
- FENC 2001
- Fundamental
- Price
- FT $7.58
- FENC $6.65
- Analyst Decision
- FT
- FENC Strong Buy
- Analyst Count
- FT 0
- FENC 2
- Target Price
- FT N/A
- FENC $14.00
- AVG Volume (30 Days)
- FT 63.0K
- FENC 53.9K
- Earning Date
- FT 01-01-0001
- FENC 03-20-2025
- Dividend Yield
- FT 7.85%
- FENC N/A
- EPS Growth
- FT N/A
- FENC N/A
- EPS
- FT N/A
- FENC N/A
- Revenue
- FT N/A
- FENC $49,348,000.00
- Revenue This Year
- FT N/A
- FENC $170.43
- Revenue Next Year
- FT N/A
- FENC $6.70
- P/E Ratio
- FT N/A
- FENC N/A
- Revenue Growth
- FT N/A
- FENC 278.09
- 52 Week Low
- FT $5.97
- FENC $3.96
- 52 Week High
- FT $7.23
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- FT 55.22
- FENC 58.24
- Support Level
- FT $7.52
- FENC $6.57
- Resistance Level
- FT $7.65
- FENC $6.96
- Average True Range (ATR)
- FT 0.08
- FENC 0.26
- MACD
- FT -0.01
- FENC -0.02
- Stochastic Oscillator
- FT 59.44
- FENC 61.25
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.